Zhejiang Jolly Pharmaceutical Co.,LTD (SHE:300181)

SHE:300181 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Operating Revenue	2,720	2,569	1,937	1,787	1,450	1,086
Other Revenue	8.95	8.95	5.2	18.23	7.26	5.32
Revenue	2,729	2,578	1,942	1,805	1,457	1,091
Revenue Growth (YoY)	28.77%	32.71%	7.61%	23.86%	33.60%	19.72%
Cost of Revenue	1,117	1,019	616.36	534.65	420.35	362.9
Gross Profit	1,612	1,559	1,326	1,271	1,037	727.98
Selling, General & Admin	952.48	949.08	874.18	921.45	794.25	601.17
Research & Development	70.8	71.94	79.38	64.43	45.63	30.39
Other Operating Expenses	-49.97	-58.7	-49.99	-42.32	-28.31	-21.62
Operating Expenses	982.27	968.57	904.42	948.8	812.78	610.52
Operating Income	630.19	590.51	421.66	321.71	224.26	117.46
Interest Expense	-10.02	-9.29	-7.62	-8.32	-12.07	-17.44
Interest & Investment Income	13.97	15.95	22	4.64	4.41	2.05
Currency Exchange Gain (Loss)	0	0	0	-0	-	-
Other Non Operating Income (Expenses)	9.75	-0.47	0.18	-0.01	-1.13	1.65
EBT Excluding Unusual Items	643.88	596.7	436.21	318.02	215.47	103.71
Gain (Loss) on Sale of Investments	-0.96	-0.66	-0.1	0.08	0.52	0.39
Gain (Loss) on Sale of Assets	0.33	0.35	0.28	-9.71	-1.92	-0.08
Asset Writedown	-7.38	-8.06	-0.53	-	-	-
Other Unusual Items	8.26	8.36	10.78	15.74	8.24	5.17
Pretax Income	644.14	596.69	446.64	324.12	222.31	109.18
Income Tax Expense	88.91	80.73	55.88	38.6	30.33	13.87
Earnings From Continuing Operations	555.24	515.96	390.76	285.52	191.98	95.31
Net Income to Company	555.24	515.96	390.76	285.52	191.98	95.31
Minority Interest in Earnings	-8.73	-8.19	-7.83	-12.51	-12.58	-6.51
Net Income	546.51	507.77	382.94	273.01	179.41	88.8
Net Income to Common	546.51	507.77	382.94	273.01	179.41	88.8
Net Income Growth	27.72%	32.60%	40.27%	52.17%	102.03%	246.98%
Shares Outstanding (Basic)	696	696	696	607	619	609
Shares Outstanding (Diluted)	696	696	696	607	619	609
Shares Change (YoY)	-0.10%	-0.10%	14.76%	-1.93%	1.64%	0.12%
EPS (Basic)	0.79	0.73	0.55	0.45	0.29	0.15
EPS (Diluted)	0.79	0.73	0.55	0.45	0.29	0.15
EPS Growth	27.85%	32.73%	22.22%	55.17%	98.77%	246.56%
Free Cash Flow	-113.83	34.16	156.75	140.56	103.84	221.34
Free Cash Flow Per Share	-0.16	0.05	0.23	0.23	0.17	0.36
Dividend Per Share	0.600	0.600	0.450	0.300	0.200	0.100
Dividend Growth	33.33%	33.33%	50.00%	50.00%	100.00%	400.00%
Gross Margin	59.08%	60.48%	68.27%	70.38%	71.16%	66.73%
Operating Margin	23.09%	22.91%	21.71%	17.82%	15.39%	10.77%
Profit Margin	20.02%	19.70%	19.71%	15.12%	12.31%	8.14%
Free Cash Flow Margin	-4.17%	1.32%	8.07%	7.79%	7.12%	20.29%
EBITDA	698.77	657.69	483.23	378.43	277.87	171.31
EBITDA Margin	25.60%	25.51%	24.88%	20.96%	19.07%	15.70%
D&A For EBITDA	68.58	67.18	61.58	56.72	53.61	53.85
EBIT	630.19	590.51	421.66	321.71	224.26	117.46
EBIT Margin	23.09%	22.91%	21.71%	17.82%	15.39%	10.77%
Effective Tax Rate	13.80%	13.53%	12.51%	11.91%	13.64%	12.71%
Revenue as Reported	2,729	2,578	1,942	1,805	1,457	1,091
Advertising Expenses	-	28	15.71	675.37	528.45	377.85

Source: S&P Global Market Intelligence. Standard template. Financial Sources.